Lung Adenocarcinoma Clinical and Molecular Data from the French West Indies

Régine Marlin's dataset contains clinical, pathological, molecular, and survival data for 159 patients diagnosed with lung adenocarcinoma in the French West Indies. The data was collected during an 18-month retrospective, population-based study at the University Hospital of Martinique. It was last updated on 2026-05-04.

Use Cases

• Analyzing the prevalence of actionable oncogenic drivers like EGFR and KRAS mutations based on molecular data.
• Studying survival outcomes, including median overall survival of 19.3 months, based on clinical and treatment data.
• Investigating diagnostic delays and early mortality patterns based on stage at presentation and survival timelines.
• Comparing treatment efficacy, such as progression-free survival for targeted therapies versus immunotherapy, based on treatment and outcome data.

Strengths

• Includes data for 159 patients, providing a specific cohort size.
• Contains integrated clinical, pathological, molecular, and survival data for each patient.
• Reports specific mutation prevalence rates, such as EGFR in 33% and KRAS in 18% of tumors.
• Provides a median overall survival figure of 19.3 months.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data reflects a specific 18-month period and geographic region, which may limit generalizability.

Provenance

Source

University Hospital of Martinique, the sole referral center on the island.

Collection Method

18-month, retrospective, population-based study including all consecutive patients diagnosed with lung adenocarcinoma.

Time Range

Covers an 18-month study period (specific dates not provided).

Freshness

Last updated 2026-05-04 05:34:18; freshness should be verified.

Geography

French West Islands (Martinique).